6 February 2017
Sonendo® Inc. today announced it has acquired PIPStek™ LLC, including all of the intellectual property for its PIPS® laser technologies. PIPStek™ LLC will continue as a stand-alone company and will be a wholly owned subsidiary of Sonendo.
1 February 2017
InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with the global contract research organization (CRO) PAREXEL for the implementation of the CONDUCT study. CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis.
31 January 2017Registration of Document E pertaining to the planned strategic combination between Genticel and Genkyotex
Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a privately-held Swiss biopharmaceutical company and the leader in NOX therapies, today announce that the information document (Document E) drawn up in relation to the planned strategic combination between the two companies announced on December 22, 2016 was registered with the French financial market authority (Autorité des Marchés Financiers - AMF) under reference number E.17-004 on January 31, 2017.
24 January 2017Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus Aureus Pneumonia
Study to evaluate safety and efficacy of ASN100 in high-risk, mechanically ventilated ICU patients.
10 January 2017
Oxular Limited, the Oxford-based retinal therapeutics company, today announces the appointment of David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Mr. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.